BPA for oxervate
Active Awarded Last action
- Contract number
- 36E79725A0004
- Awardee
-
Dompe U.s. Inc. UEI ECCDSKQAN2J3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 85% complete
- IDV ceiling
- $49,717.65
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Dompe U.S. Inc., a pharmaceutical manufacturer headquartered in San Mateo, California, has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center for the supply of Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution. This BPA, valued at $49,717.65 with a ceiling effective through February 18, 2027, is issued under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule (FSS-61-IB) and represents the exercise of an option year under the existing contract vehicle. As a specialized pharmaceutical treatment for neurotrophic keratitis, Oxervate addresses a critical medical need within the VA healthcare system. The contract operates without set-aside designations and enables the VA to issue firm fixed-price delivery orders across multiple Veterans Integrated Service Networks (VISNs) nationwide.
This BPA complements Dompe U.S. Inc.'s established federal contract portfolio with the VA, which includes a $10 million BPA and a $5 million Federal Supply Schedule contract, all focused on ensuring consistent and reliable access to Oxervate for VA medical facilities. Delivery orders placed under this vehicle have historically ranged from approximately $18,000 to $159,000 per order and support both ongoing pharmaceutical requirements and emergency medical needs at VA healthcare locations. The award date of February 19, 2025, with an ultimate completion date of February 18, 2027, establishes a two-year performance window for fulfilling the VA's ophthalmic pharmaceutical requirements through this single-award contract vehicle.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0004?
36E79725A0004 was awarded to Dompe U.s. Inc. by National Acquisition Center (Headquarters) on February 19, 2025.
How much is contract 36E79725A0004 worth?
36E79725A0004's own ceiling is $49,718.
Who can order from contract 36E79725A0004?
36E79725A0004 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0004 under another contract?
Yes. 36E79725A0004 is a blanket purchase agreement under 36F79720D0017, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0004 competed?
The extent of competition for 36E79725A0004 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV